NEW

with lidocaine

Optimal
skin
integration

Belotero ®

Its a part
of me

The filler you‘ll love

Belotero® – It‘s a part of me

It's a part of you

Belotero® offers you an extended range for smoothing and filling wrinkles, restoring facial
volumes and rehydrating skin.

It's a part of them

Belotero® integrates smoothly into an anti-ageing regimen that enhances confidence and
self-assurance. It has an intelligent design for an advanced bespoke aesthetic solution with
predictable and natural outcomes for optimal patient satisfaction and trust.

Belotero® Hydro is an ideal treatment option to deliver effective results when patients want
deep rehydration and firmer skin.
The Belotero® range of fillers delivers predictable and harmonious results for the smoothing
and filling of lines and wrinkles, lip augmentation and the restoring of facial volumes.

Belotero® range of fillers now with lidocaine

Improved patient comfort
 The addition of the anesthetic, lidocaine, enhances patient comfort in more sensitive areas
 The influence of lidocaine endures after the injection procedure

®
Belotero® – Holistic solution for targeted needs

The Belotero® products can be used individually or in combination to tailor an

aesthetic solution for each patient depending on the skin’s structural and functional needs.

What does the skin need?

Elasticity – Cohesivity –
for optimal for excellent
tissue support tissue integration

Plasticity –
for excellent
malleability to

Seite kürzen
model and
shape

Elasticity – Cohesivity – Plasticity –

the ability of a the ability the ability of
gel to return to of a gel to a gel to be
its initial shape stick together shaped and
after being and thereby modelled
subjected to maintaining gel
strain integrity

The Cohesive Polydensified Matrix of Belotero® enables seamless dermal integration1

Control Cohesive gel Fragemented gel Non cohesive gel
Monophasic Monophasic Biphasic
polydensified monodensified gel

By optimising the balance of these properties, the Belotero® range of fillers integrates
seamless into the skin tissue and lets you achieve predictable and harmonious results.

®
1
Van Gieson elastin staining
 Intelligent design in aesthetics

The Belotero® fillers are manufactured using a patented Dynamic Cross-Linking

Technology that results among others in a monophasic Cohesive Polydensified
Matrix (CPM).

Phase 1 Phase 2 Phase 3

Hyaluronic acid in its original form Linearisation of the individual First hyaluronic acid crosslinking
(single chains, random coil structure) hyaluronic acid chains: process with BDDE:
the random coil structure untangles a cellular, monophasic gel emerges

StandarD cross-linking
Seite kürzen

Phase 4 to 5 constitute the innovative part of the patented DCLT technology

Phase 4 Phase 5
Expansion of the gel that was created Second crosslinking process,
in the crosslinking process supplemented with additional
non-crosslinked hyaluronic acid

Patented dynamic cross-linking technology (DCLT)2

This advanced DCLT technology provides the ideal balance of cohesivity, elasticity and
plasticity to match the needs of the targeted layer of the skin.

®
2
Patent family publication number WO2005/085329
 Hydro
Belotero ®

Hydro
Skin reh
Comple ydra
xion tio
ra n
dian
ce
Belotero® Hydro* – Designed for rehydration whilst
restoring skin radiance and skin elasticity

HA + Glycerol – A unique and patented combination3: Made with naturally occurring

substances thus perfectly biocompatible and totally resorbable.

H2O

H2O H2O H2O

H2O H2O H2O Glycerol

Glycerol H2O H2O H2O
H2O H2O H2O

H2O H2O Glycerol

a • ha • ha • h
ha •
ha • ha •
ha H2O H2O
•h a •h
H2O Glycerol H2O
a• • • a•
•h ha
ha ha H2O • ha
ha

H2O ha a•
ha • ha • h

•
•
•h

Glycerol

a
H2O H2O

•h
Glycerol Glycerol H2O
H2O •h a • ha • ha
a

• ha • •h
ha
ha a •h
•h • ha a•
• h a• a ha • ha
ha • •h

•
ha • ha Glycerol H2O

a
H2O H2O
a

•h
•h

H2O
H2O H2O Glycerol H2O

a
H2O
a•

•h
Glycerol H2O
Glycerol
ha

a
• h H2O H2O
ha • ha • ha • ha • ha
•

H2O H2O H2O a•

ha

H2O
H2O •h
•

a H2O H2O
•h
ha

a Glycerol
•h

a
•h a •h Glycerol
a • ha • ha • h H2O H2O

H2O H2O H2O H2O

Glycerol H2O
Glycerol
H2O H2O

H2O Glycerol acts as a proctective

sheath around the HA

Composition Amount Purpose

High molecular weight, non- 2.5 –3 MDa, 18 mg/ml Known as a hydrating agent and
crosslinked highly concentrated for its inhibition of matrix-metallo-
Hyaluronic Acid (HA) proteinase (MMP) which degrades
collagen4

Glycerol 21 mg/ml Known for its ability to hydrate

and acts as a ‘protective sheath’ to
slow HA degradation and hence
increase duration of action5

Phosphate-citrate buffer pH 7 To adjust and maintain a

physiological pH

* Belotero® Hydro is equivalent to Mesolis® +,

a registered trademark of Anteis S.A.
3
Patent family publication number WO2007/077399 ®
4
Sasaki A et al., Tohoku J. Exp. Med., 2004, 204, 99-107.
5
Fluhr J. W. et al., Br J Dermatol. 2008 Jul; 159(1): 23-34.
 Additional benefit: The addition of glycerol prevents
HA degradation caused by free radicals

In vitro tests show the increased resistance against free radical degradation of an HA gel
combined with glycerol.6

100.0

10.00

01.000
G‘ (Pa)

0.100

0.010

Seite kürzen
0
0 500.0 1000 1500 1500 2500 3000 3500 time (s)

Gel based on HA and glycerol

Gel based on HA without glycerol

86%
of females want
to look radiant
and rested7

6
Data on file ®
7
Face Value Wave I (n = 2939) – page 11 –
internal data Merz Pharmaceuticals GmbH
 Belotero® Hydro ensures a high level of satisfaction
for you and your patients8

Very high practitioner satisfaction with an average score of 9.2/10

9.35 9.09 9.35 8.78 9.32 9.32

10

6
Score

aesthetic effect radiance health colour elasticity fines lines or

at the end of the of the skin of the skin of the skin of the skin crumpled effect
treatment visibility
smoothed
Seite kürzen

Excellent patient appreciation with an average score of 8.9/10

10 8.89 8.76 8.88 8.97 9.14

6
Score

radiance health colour elasticity fines lines or

of the skin of the skin of the skin of the skin crumpled effect
visibility smoothed

8
In 2009 a satisfaction enquiry on Mesolis+ gel (equal to
Belotero® Hydro) was conducted on an international level.
During that period, 113 patients and 23 practitioners ®
evaluated the product itself and the quality of the aesthetic
outcomes.
Belotero® Hydro is specifically designed for deep
rehydration treatments

Practical guidance for treatment phases

1 st 2 nd 3 rd
Injection Injection Injection

Initial
treatment phase Maintenance phase
2 months

Initial treatment phase: Maintenance phase:

2 – 3 treatment sessions Following this treatment trilogy, maintenance
held 30 days apart are treatments should follow once or twice a year
recommended in the initial depending on the individual patient

Seite kürzen
treatment phase

Tips for the initial physician – patient consultation

Belotero® Hydro may be an entry level treatment for those who have never previously
considered aesthetic therapy.

The choice of when to begin a treatment is a sensitive one for patients, and
helpful information prior to your recommendation can be gathered through a few
quick yes/no questions.

 Is your skin often exposed to the sun?

 Does it feel as though it’s lost some firmness?
 Are more fine lines noticeable of late?
 Are you a smoker?

If the answers tend to be positive, the likelihood is high that candidates will be suited
to a Belotero® Hydro regimen.

®
 Predictable results with Belotero® Hydro*

Face: Recovery of skin elasticity and firmness

Before After

Neck: Recovery of skin tone and elasticity

Seite kürzen

Before After

Back of hands: Improvement of skin texture and radiance

Before After

®
* Courtesy of Dr Lampignani
 SOFT
Optimal
skin
integration

Belotero Soft
®
Belotero® Soft* smoothens fine lines away

Belotero® Soft is optimal for fine line correction and deep rehydration
due to its excellent cohesivity and its water binding capacity.9

Ideal for fine lines such as

 Crow´s feet
 Perioral lines

Superficial
injection for fine
line correction

* Belotero® Soft is equivalent to Esthélis® Soft,

a registered trademark of Anteis S.A. ®
9
J. Necas, L. Bartosikova, P. Branner, J. Kolar, Veterinarni
Medicina, 53, 2008 (8): 397-411.
A product for superficial injection techniques

Blanching technique for natural looking results

Belotero® Soft can be administered using the blanching as well as the micro-papular injection
technique for deep hydration and fine line smoothing.

Lateral view Top view

Seite kürzen
Safe injections close to the surface without Tyndall effect10

 Inject at the correct depth and there

is brief skin blanching at the point of
injection

 The whiteness disappears after a few

minutes

Directly after injection

Picture: Courtesy P. Micheels

Micheels P. et al., A Blanching Technique forIntradermal Injection of
10  ®
the Hyaluronic Acid Belotero. Plastic and Reconstructive Surgery.
2013; October Supplement.
 Predictable results with Belotero® Soft*

Crow's feet

Before After

Perioral lines
Seite kürzen

Before After

®
* Courtesy of Dres Imhof/Kühne
 BALANCE
Optimal
skin
integration

Belotero
®

Balance
Belotero® Balance* becomes a part of your patients due to
its seamless integration

Cohesivity
Elasticity Belotero® Balance

Plasticity

The cohesivity of Belotero® Balance enables optimal skin integration

and prevents the risk of gel migration

 Belotero® is seen to occupy the full thickness of the reticular dermis and is evenly distributed11
 No dermal trauma or structural alteration11

Cohesivity enables seamless dermal integration12

Control Cohesive gel Fragemented gel Non cohesive gel

Monophasic Monophasic Biphasic
polydensified monodensified gel

D8

D114

High cohesivity Low cohesivity

Blue areas on the images correspond to HA
Alcian blue staining 8 days after injection of HA fillers
Alcian blue staining 114 days after injection of HA fillers

* Belotero® Balance is equivalent to Belotero® Basic

as well as equivalent to Esthélis® Basic, a registered
trademark by Anteis S.A.
11
Tran C, Carraux P, Micheels P, Kaya G, Salomon D: In
vivo Bio-Integration of Three Hyaluronic Acid Fillers in
Human Skin: A Histological Study. ®
In press, Dermatology DOI: 10.1159/000354384
12
Van Gieson elastin staining
Belotero® Balance – Good safety and tolerability

Optimal skin integration without side effects

Belotero® ultrasonography images show a homogenous papule which is as dense as the

surrounding tissue after injection into the superficial dermis.13

Biphasic gel Monophasic monodensified gels Monophasic polydensified gel

In contrast Restylane® and Juvéderm® showed a higher degree of echoes, opaqueness, and
production of a cone of shadow underneath the injected papules.

Seite kürzen
Belotero® has no significant local inflammatory reaction14
Belotero® showed an absence of an inflammatory reaction following injection intradermally.14

Histological slides 30 days after injection

LY, PZ
and EG FM
LY, PZ and EG
E

FM

Juvéderm® 30HV Teosyal® Deep Lines Restylane Perlane® Belotero® Balance

- Slight to moderate degree - Severe chronic - Intense chronic - Histomorphological normal

of chronic inflammation inflammation inflammation, finding free of inflamma-
- Subepidermal and perivas- - Dense infiltrate of - Heavy infiltration of tion unremarkable immune
cular increased number of inflammatory cells lymphocytes, plasma reaction
lymphocytes, also plasma cells and eosinophil
cells and several granulo- granulocytes
cytes

LY lymphocytes, PZ plasma cells, EG eosinophilic granulocytes, FM foreign material, E epidermis

13
 Micheels P et al., Dermatol Surg 2012;38:1162–1169 ®
Pictures: Courtesy to Dr Micheels and Dr Besse
14
Taufig A.Z. et al., J Ästhet Chir 2009 2:29 – 36.
 Ideal for blanching

Belotero® is the only commercially available HA filler that can be administered with the
blanching technique in the superficial dermis15
Seite kürzen

The multipuncture deposition of the cohesive polydensified

matrix hyaluronic acid gel for the blanching technique.

Important: 1.5 to 2 mm needle insertion

 Injection in superficial dermis

 Injection angle of 10 –12 degrees
 Multiple punctures at intervals of 0.5 cm

“Belotero is suitable for very superficial intradermal injection using the blanching
®

technique with little to no risk of visible product or the Tyndall effect.”

15
 icheels P. et al. A Blanching Technique for
M
Intradermal Injection of the Hyaluronic Acid ®
Belotero. Plastic and Reconstructive Surgery.
2013; October Supplement.
 Belotero® Balance offers smooth support of the
superficial and mid dermis

The Split-Face Evenness Study showed significantly greater improvement in evenness* of

the nasolabial folds area of Belotero® Balance compared with Restylane® (p < 0.0001).16

Restylane®
*Evenness was measured by
the mean residual depth of the
nasolabial target area relative to
the skin surface post treatment.

Seite kürzen
Two-dimensional surface profiles before and 4 weeks after treatment

Belotero® Balance Before treatment

After treatment
200 The total waviness of the nasolabial
target area, i.e. depth and evenness
Mean depth (μm)

100 was measured from the surface of

the skin. Positive figures implied
0 “bumps” in the skin and negative
-100 figures implied lines, wrinkles and
folds in the skin.
-200
At week 4, the Belotero® treatment
-300 achieved a reduction of 109.5 μm
0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00 (from 248.8 μm to 139.4 μm) in the
length (mm) mean depth of the nasolabial fold,
compared to a reduction of 71.8 μm
in the Restylane® treated side.

Restylane® Before treatment

After treatment
200
Mean depth (μm)

100
0
-100
-200
-300
0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00
length (mm)

16
 rager W, Steinkraus V. A prospective, rater-blind,
P
randomized comparison of the effectiveness and
tolerability of Belotero Basic versus Restylane ®
for correction of nasolabial folds. Eur J Dermatol
2010; 20 (6): 748-52.
 Belotero® Balance – Tried and tested

The safety of Belotero® Balance has been evaluated in 8 clinical studies17–24

In general the following were observed:

 Mild to moderate treatment-related adverse events

 No treatment-related serious adverse events
 Minimal inflammatory response
 Proven tolerability over 18 months
 Patient and physician satisfaction
 Long-term safety and patient satisfaction
 Belotero® is safe in Fitzpatrick skin types IV – VI21
 No reports of severe adverse events

Tolerability over 18 months23

Seite kürzen

In a long-term open-label extension study for correction of nasolabial folds, Belotero® was
well tolerated when repeat injections were given over an 18-month follow-up period.

Injection site bruising was the only adverse event that was considered to be related to Belotero®.

Patients and physicians are satisfied with Belotero®17

A clinical study in 114 patients with nasolabial folds demonstrated that 81 % of patients
were treated successfully for 24 weeks with the effect persisting for 36 weeks in 66% of the
patients.
There was good or very good tolerability in 109 out of the 114 patients.

98% of all patients and 90% of the examiners rated the treatment success as good
or very good.

17
Reinmüller J et al, Dermatol News 2007; issue 11: 2-3.
18
Taufig AZ, et al, J Ästhetische Chirurgie 2009; 2: 29-36.
19
Prager W et al, Dermatol Surg 2012;38:1143–1150.
20
Micheels P, J of cosm surg & med, VOL 4, No. 3 2009.
21
Downie JP et al, Plast Reconstr Surg, 132; 41S; Oct,
Suppl 2013.
22
Narins RS et al, Dermatol Surg, 2010;36:730-740. ®
23
Narins RS et al, Dermatol Surg, 2010; 36:1800-1808.
24
Kühne U et al, J Drugs Dermatol 2012;11:1032–1035.
Predictable results with Belotero® Balance*

Nasolabial wrinkle

Before After

Glabella wrinkle

Seite kürzen
Before After

Nasolabial wrinkle

Before After

®
* Courtesy of Dres Imhof/Kühne
 Predictable results with Belotero® Balance

Nasolabial wrinkle *1

Before After
Courtesy: Dr J Reinmüller,
Courtesy: Dr
Germany
J Reinmüller, Germa

Nasolabial wrinkle *2
Seite kürzen

Before After
Courtesy: Fiona &Courtesy:
Marie Aesthetics
Fiona & Marie
Ltd, UK
Aesthetics

Courtesy: Dr J Reinmüller,
Courtesy: Dr
Germany
J Reinmüller, Germa
®
*1 Courtesy of Dr Reinmüller
*2 Courtesy of Merz Pharma UK Ltd.
 Belotero
®

Intense

Optimal
Tissue

INTENSE
Support
Belotero® Intense* offers effective filling capacity and
natural looking results due to balanced elasticity

Finding the right elasticity to suit your patients’ needs and expectations is a matter of
balance in order to provide optimal skin support.

Cohesivity

Elasticity
Belotero® Intense

Plasticity

Belotero® Intense provides optimal filling capacity for predictable, natural looking results
whilst maintaining excellent tissue integration to minimise lumps and bumps.

®
* Belotero® Intense is equivalent to Fortélis® Extra,
a registered trademark by Anteis S.A.
 Efficacy was demonstrated in a study of 149 patients to
assess the efficacy and safety of Belotero® Intense25

Mean WSRS improved significantly by 1.9 score points without any decline throughout the
12-week period.

4.5
3.98 *p < 0.001
4

3.5

3
Mean WSRS Score

2.5 2.28 *
2.04 * 2.07 *
2

1.5

0.5

0
Baseline Immediately 2 weeks 12 weeks
Post-Injection

Seite kürzen
89.9 % of patients achieved improvement on the Investigator assessed Global Aesthetic
Improvement Scale immediately after injection. The aesthetic effect was well maintained
throughout the 3-month evaluation period.

70
59.7 59.7 57.0
60

50

40 Very much/
33.6 33.6
Patients (%)

30.2 Much improved

30 Improved
No change
20
Worse
9.4 Not determined
10
2.7 4.0 4.7 4.7
0.7 0.0 0.0 0.0
0
Immediately 2 weeks 12 weeks Time Post-injection

Adverse events were localised to the injection area and occurred in 85.9 % of patients
immediately after injection and declined to 12.8 % in week 2. None were serious.

25
 avicic T. Efficacy and Tolerability of a New Monophasic,
P
Double-Crosslinked Hyaluronic Acid Filler for Correction of ®
Deep Lines and Wrinkles. Journal of Drugs in Dermatology.
2011. 10(2); 134-139.
 Belotero® Intense provides lasting results and high
patient satisfaction without producing lumps26

A double-blind, half-side comparison study of 20 patients with symmetric nasolabial folds

who were randomised to contralateral treatment with Belotero® Intense and a biphasic
HA filler (NASHA). Efficacy was assessed at baseline and after 2, 24, and 48 weeks using a
wrinkle severity rating scale, subject questionnaire, and biophysical in vivo methods.

Lasting results
All subjects showed significant improvements with both fillers up to day 365.

Patient satisfaction
At week 24, improvement of patient satisfaction was significantly greater with Belotero®
Intense, p < 0.001; NASHA, p = 0.006).
24 and 48 weeks after initial injection, significantly more subjects treated with Belotero®
Intense judged themselves as satisfied compared with NASHA (24 weeks: p = 0.002;
48 weeks: p = 0.005).

WSRS * by subject (changes to baseline in percent)

Seite kürzen

week 2 week 24 week 48

0 Biphasic NASHA
Changes to baseline (%)

-5 Belotero® Intense
-10
-15
-20 -17
-22 -21
-25
-30
-31
-35
-36
-40
* WRS = wrinkle severity rating scale
-50
-49

After 48 weeks patient satisfaction with Belotero® Intense was significantly greater than at
baseline but satisfaction on the NASHA had returned to baseline value.
Subject questionnaire confirmed that 80% of subjects treated with Belotero® Intense
and 65% of subjects injected with NASHA filler stated that their expectations were met
and that they would repeat the treatment course.

“These results may be due to the unique structure of Belotero Intense which allows
®

it to spread more regularly and fill the dermal volume defect more evenly than the
biphasic product.”

26
 untrock H, Reuther T, Prager W, Kerscher M. Efficacy,
B
safety, and patient satisfaction of a monophasic cohesive
polydensified matrix versus a biphasic nonanimal ®
stabilized hyaluronic acid filler after single injection in
nasolabial folds. Dermatol Surg. 2013; 39(7):1097-105.
Minimal risk of local inflammatory reaction
with Belotero® Intense compared to others27

A study to assess the safety criteria of aesthetic filler materials by investigating intradermal
reactions after implantation of 0.2 ml dermal filler in mapped abdominal skin areas showed
no abnormality and no significant local inflammatory reaction after Belotero® injection.

Histological slides 30 days after injection

Lymphocytes (L)
Plasma cells (P)
Eosinophil granulocytes (EG)

BELOTERO® Intense Juvéderm® 30HV

No findings

HE stain, x20 HE stain, x20

P

Seite kürzen
■ No histomorphological inflammation reaction ■ Light to moderate chronic inflammation
■ Even distribution of injection material ■ Increased lymphocytes, plasma cells, and
eosinophil granulocytes
■ Irregular distribution of injection material

Restylane Perlane® Teosyal® Deep Lines

L, P and EG
L and P
L and P

HE stain, x20 HE stain, x20

■ Intense chronic inflammation ■ Intense chronic inflammation

■ Heavy infiltration of lymphocytes, plasma cells, ■ Irregular infiltration of lymphocytes and
and eosinophil granulocytes plasma cells
■ Irregular distribution of injection material

27
 aufig A, et al., A new strategy to detect intrader-
T ®
mal reactions after injection of resorbable dermal
fillers. J Ästhetische Chirurgie 2009; 2: 29-36.
 Predictable results with Belotero® Intense*

Lip augmentation

Before After

Face contours, nasolabial folds and lip enhancement

Seite kürzen

Before After

Nasolabial folds and lip enhancement

Before After

®
* Courtesy of Dr Micheels
Optimal
Modelling
capacity

VOLUME
Belotero
®

Volume
Belotero® Volume* models and restores facial volumes
due to its tailored plasticity

Cohesivity
Elasticity

Plasticity
Belotero® Volume

The intelligent and well-balanced design offers 3 advantages:

Excellent malleability to model and shape as desired maintaining a natural look

Powerful volumising effect for reliable and predictable results:

100 % of practitioners considered Belotero® Volume as superior or equivalent to competitors28

High plasticity facilitates easy placement of the gel after injection.

Very low ejection force that gives you the respective freedom to operate29

Ejection force (N) 25G1 Ejection force (N) 22G 50 mm

Terumo needle** Softfil cannula**
Belotero® Volume
24.0 21.8
(25G1, 22G 50 mm
Juvéderm Voluma
50.6 42.9
(23G1“, 18G 70 mm)
Restylane Sub-Q
37.1 30.6
(21G)

* Belotero® Volume is equivalent to Modélis®Shape,

a registered trademark bei Anteis S.A.
**  1 ml of product was injected with the 25G1 Terumo
needle and 1 ml with the 22G 50 mm Softfil cannula.
28
Clinical Evaluation Report VP1-1001: An open label and multi-
centre clinical evaluation assessing the efficacy and safety of
Modélis in facial depressions (9 injectors from France, Switzer- ®
land, Thailand, Germany and Belgium), February 2012.
29
Data on file, Belotero® Volume US product information page 6.
Clinically proven efficacy and safety
with high patient satisfaction

In a post-marketing clinical follow-up of 33 patients to assess the efficacy and safety of

Belotero® Volume (2ml syringe) in the treatment of volume loss over 18 months after
injection, the mean face volume loss score (FVLS) at each follow-up visit was significantly
lower than mean FVLS baseline score.30

Although there was a slight increase in FVLS over time, the effectiveness of Belotero®
Volume was still significant at month 12 and month 18.

Facial volume score

Clear visibility of
underlying musculature 5.0

*p  < 0.05, paired student t-test

Intermediate between

Seite kürzen
grades 3 & 5 4.0

May have visibility of

underlying musculature 3.0

Intermediate between
grades 1 & 2 2.0 * *
* *
* *
No visibility of *
underlying musculature 1.0

SCR D1 M1 M3 M6 M9 M12 M18

= 33 = 19 n = 28 n = 28 n = 31 n = 25 n = 30 n = 20

Visits

At month 12 and month 18, the mean Global Aesthetic Improvement Scale score is still
“Much improved”, supporting the FVLS results.

13 patients experienced at least one injection site reaction during the evaluation. Main site
reactions were redness and pain of mild intensity which disappeared before the next follow-
up visit.

Most patients [93 % (n=28) at month 12 and 90 % (n=18) at month 18] were satisfied with
their results and were intending to repeat the treatment and recommend it to their friends.

®
* SCR=screening visit, corresponds to D1 before injection
30
Data on file. Clinical Evaluation Report. Section VI
 Predictable results with Belotero® Volume*

Cheekbones

Before After

Cheekbones
Seite kürzen

Before After

Temples

Before After

®
* Courtesy of Dr Vandeputte
PORTFOLIO
The Belotero® family – It's a part of you

HA Needle
Belotero® product Indications Injection site and angle
concentration size

Hydro Skin rehydration, e.g.: face, 18 mg/1ml 30 G Dermal/epidermal junction

neck, décolletage, back of (nappage technique) or
hands superficial dermis (micro-
papular technique)

SOFT Correction of fine lines, e.g.: 20 mg/1ml 30 G Superficial dermis

crow‘s feet, perioral lines, Approx 10°
fine forehead lines

Balance Correction of moderate 22.5 mg/1ml 27 G Superficial to mid dermis

lines, e.g.: moderate Approx 15°
nasolabial wrinkle,
glabellar lines, moderate
perioral wrinkles,
lip contouring, philtrum

intense Correction of deeper lines, 25.5 mg/1ml 27 G Mid and deep dermis
e.g.: severe nasolabial fold, Approx 30°
lip volume, oral commissures,
marionette folds

volume Restoration of facial volumes, 26 mg/1ml 30 G + Deep dermis,

e.g.: cheeks, temples, facial 27 G subcutaneously
volume loss Needle
27 G
Cannula

®
 NEW
Belotero® Lidocaine

Date of preparation May 2014

Belotero® is a registered trademark of Merz Pharma GmbH & Co. KGaA.

Merz Pharmaceuticals GmbH, Eckenheimer Landstraße 100
60318 Frankfurt am Main, Germany
www.merzaesthetics.com